Revisiting Stem Cell-Based Clinical Trials for Ischemic Stroke

Abstract

Stroke is the leading cause of serious long-term disability, significantly reducing mobility in almost half of the affected patients aged 65 years and older. There are currently no proven neurorestorative treatments for chronic stroke. To address the complex problem of restoring function in ischemic brain tissue, stem cell transplantation-based therapies have emerged as potential restorative therapies. Aligning with the major cell types found within the ischemic brain, stem-cell-based clinical trials for ischemic stroke have fallen under three broad cell lineages: hematopoietic, mesenchymal, and neural. In this review article, we will discuss the scientific rationale for transplanting cells from each of these lineages and provide an overview of published and ongoing trials using this framework.

Neurological disorders in patients with long COVID syndrome and cell therapy methods for their correction a literature review

“…Однако при внутрисосудистом пути введения используется значительно большая доза клеток (50-600)×10 6 мононуклеаров), чем при непосредственном введении в ЦНС (интрамозговые, интратекальные или интравентрикулярные инъекции), что является ограничивающим фактором для амбулаторного получения материала от пациентов, как правило, требует их краткосрочной госпитализации и существенно увеличивает риски развития побочных эффектов и стоимость лечения [46,47]. При этом, как позднее было показано, биораспределение внутриартериально и внутривенно трансплантированных аутологичных мононуклеарных клеток, полученных из костного мозга, сопоставимо с введением значительно меньшего их количества непосредственно к очагу поражения в ЦНС [48].…”

Optimization of Multimodal Nanoparticles Internalization Process in Mesenchymal Stem Cells for Cell Therapy Studies

“…A recent review in stroke clinical trials (mainly phases I or II) demonstrated that stem cells are safe, and now there is an ongoing evaluation in neuro-regeneration and sequelae reduction. However, the heterogeneity of these studies' design and evaluation criteria can interfere with clear conclusions about the efficacy of these treatments [4][5][6][7][8].…”

Neural Stem Cells for Early Ischemic Stroke

“…Furthermore, therapeutic outcomes of NSCs can be different based on time and route of NSC administration. While current clinical trials focus on the outcome of stem cells on neuro-restoration by injecting cells during the chronic stroke stage [ 25 ], this review will focus on the therapeutic mechanisms and potential of NSC transplantation in the early (subacute) phase of ischemic stroke, thus improving long-term outcome.…”